TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10770189

Group type: EXPERIMENTAL
Intervention: Recombinant human GH (0.1 IU/kg day)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Recombinant human GH (0.2 IU/kg day)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 9413087

Group type: EXPERIMENTAL
Intervention: Purified chick embryo cell rabies vaccine
Number of subjects: 72

Group type: COMPARATOR
Intervention: Human diploid cell rabies vaccine and human rabies immune globulin
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Chick embryo vaccine without immune globulin
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Chick embryo rabies vaccine with immune globulin
Number of subjects: 72
Study: 8405014

Group type: EXPERIMENTAL
Intervention: 0.150 mg desogestrel + 2.0 mg micronized 17 beta‐oestradiol
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 0.150 mg desogestrel + 0.500 mg 17 beta‐oestradiol cyclo‐octyl acetate
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 0.150 mg desogestrel + 1.0 mg 17 beta‐oestradiol decanoate
Number of subjects: 9
Study: 2939221

Group type: EXPERIMENTAL
Intervention: Single intravenous ketanserin (0.15 mg/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Single oral ketanserin (40 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Chronic oral ketanserin (40 mg once-daily)
Number of subjects: 10
Study: 30760444

Group type: EXPERIMENTAL
Intervention: Supraglottic airway device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tracheal intubation
Number of subjects: 0
Study: 29940055

Group type: EXPERIMENTAL
Intervention: Single-shot adductor canal block (SS-ACB) with 20 mL of 0.5% ropivacaine preoperatively and saline boluses at 12 and 24 hours postoperatively
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Continuous adductor canal block (C-ACB) with 20 mL of 0.5% ropivacaine preoperatively and at 12 and 24 hours postoperatively
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group receiving saline preoperatively and postoperatively
Number of subjects: 75
Study: 27145958

Group type: EXPERIMENTAL
Intervention: Mediterranean calorie‐restricted diet (n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Vegetarian calorie‐restricted diet (n = 50)
Number of subjects: 100
Study: 24114435

Group type: EXPERIMENTAL
Intervention: Estradiol (E₂) supplementation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Estradiol (E₂) concentrations
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: E₂ and BMI
Number of subjects: 24
Study: 22950868

Group type: EXPERIMENTAL
Intervention: Rescripted Image repetition
Number of subjects: 55

Group type: COMPARATOR
Intervention: Index Image repetition
Number of subjects: 55
Study: 20485221

Group type: EXPERIMENTAL
Intervention: Traditional balance training
Number of subjects: 35

Group type: COMPARATOR
Intervention: Computer feedback balance training
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Combined group (both interventions)
Number of subjects: 35
Study: 18554755

Group type: EXPERIMENTAL
Intervention: Anti-helminthic therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (upon stimulation with Con A)
Number of subjects: 0
Study: 11683039

Group type: EXPERIMENTAL
Intervention: Mizolastine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mizolastine/ASA combination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mizolastine (10 nM) in vitro
Number of subjects: 0
Study: 9471022

Group type: EXPERIMENTAL
Intervention: IFN‐alpha at a dosage of 2‐4 mega units/square metre of body surface area thrice weekly for 6‐12 months
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Higher dosage and longer treatment duration of IFN‐alpha for patients infected with HCV genotype 1b
Number of subjects: 142
Study: 7525125

Group type: EXPERIMENTAL
Intervention: Casodex 150 mg daily
Number of subjects: 23
Study: 3598162

Group type: COMPARATOR
Intervention: lactulose (30 ml/6 h)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: lactitol (12 g/6 h)
Number of subjects: 40
Study: 31793418

Group type: EXPERIMENTAL
Intervention: Topical Cannabidiol Oil (250 mg CBD/3 fl. oz)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 29681047

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5%
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25%
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 28138986

Group type: EXPERIMENTAL
Intervention: Stretch training (5 times per week for 6 weeks)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (nonstretched) of 10 males
Number of subjects: 11
Study: 26524798

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (1 mg s.c. injection three days after embryo transfer)
Number of subjects: 199

Group type: COMPARATOR
Intervention: No leuprolide acetate (control group)
Number of subjects: 199
Study: 23456328

Group type: EXPERIMENTAL
Intervention: Phonemic anadromes (e.g., sub when bus is the target)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unrelated words (well)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Words that share the same vowel but not the same set of phonemes (sun)
Number of subjects: 0
Study: 21323540

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (0.625 mg in 0.025 ml of solution)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Conventional laser therapy
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab
Number of subjects: 150
Study: 17997442

Group type: EXPERIMENTAL
Intervention: Parenteral estrogen (polyestradiol phosphate)
Number of subjects: 697

Group type: COMPARATOR
Intervention: Total androgen blockade
Number of subjects: 697
Study: 17214343

Group type: EXPERIMENTAL
Intervention: Multimodal approach incorporating CA125 as a primary test and ultrasound as a secondary test
Number of subjects: 0

Group type: COMPARATOR
Intervention: Various screening strategies
Number of subjects: 0
Study: 14614166

Group type: EXPERIMENTAL
Intervention: Fetal endoscopic tracheal occlusion
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard postnatal care
Number of subjects: 24
Study: 10881252

Group type: EXPERIMENTAL
Intervention: Temporal variant frontotemporal dementia (tv‐FTD)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Frontal variant frontotemporal dementia (fv‐FTD)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Early dementia of Alzheimer type (DAT)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 35
Study: 8939347

Group type: EXPERIMENTAL
Intervention: Mastalgia (cyclical and characterized by tenderness with pain)
Number of subjects: 1394

Group type: EXPERIMENTAL
Intervention: Cyclical mastalgia associated with tenderness and pain
Number of subjects: 1394

Group type: EXPERIMENTAL
Intervention: Breast swelling
Number of subjects: 1394

Group type: EXPERIMENTAL
Intervention: Mastalgia associated with breast swelling
Number of subjects: 1394
Study: 1415405

Group type: EXPERIMENTAL
Intervention: Amnioinfusion
Number of subjects: 437

Group type: COMPARATOR
Intervention: Control (no amnioinfusion)
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Amnioinfusion (subgroup vaginal delivery)
Number of subjects: 437

Group type: COMPARATOR
Intervention: Control (subgroup vaginal delivery)
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Amnioinfusion (subgroup cesarean delivery)
Number of subjects: 437

Group type: COMPARATOR
Intervention: Control (subgroup cesarean delivery)
Number of subjects: 437
Study: 30971374

Group type: EXPERIMENTAL
Intervention: Motivational intervention of obesity with a previously trained nurse (G1)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Motivational group with digital platform support and motivated physical activity program (G2)
Number of subjects: 123
Study: 29953441

Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention for one year
Number of subjects: 320

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention
Number of subjects: 320
Study: 27618916

Group type: EXPERIMENTAL
Intervention: Zhengtian Capsule
Number of subjects: 360

Group type: COMPARATOR
Intervention: Flunarizine
Number of subjects: 360
Study: 24126172

Group type: EXPERIMENTAL
Intervention: Higher left ventricular ejection fraction or pulse pressure
Number of subjects: 6632

Group type: EXPERIMENTAL
Intervention: Increased baseline PWV
Number of subjects: 6632

Group type: EXPERIMENTAL
Intervention: Baseline mean arterial pressure <90 mm Hg
Number of subjects: 6632
Study: 23059435

Group type: EXPERIMENTAL
Intervention: Acupuncture (30 min twice a week for 5 weeks)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Acupuncture and Chinese herbs (acupuncture 30 min twice a week for 5 weeks; herbs taken three times a day)
Number of subjects: 19
Study: 19110146

Group type: EXPERIMENTAL
Intervention: Recombinant Tissue Plasminogen Activator (rt-PA)
Number of subjects: 1899

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1899

Group type: EXPERIMENTAL
Intervention: NIHSS score change
Number of subjects: 1899

Group type: EXPERIMENTAL
Intervention: NIHSS score improvement of at least 55% in moderate stroke severity (baseline NIHSS score 7-15)
Number of subjects: 1899
Study: 18257968

Group type: EXPERIMENTAL
Intervention: NOS1 (G‐84A_exon 1c promoter polymorphism)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: NOS3 (Glu298Asp)
Number of subjects: 95
Study: 15709939

Group type: EXPERIMENTAL
Intervention: Various psychotherapy treatments tested in 236 studies
Number of subjects: 427

Group type: COMPARATOR
Intervention: Control groups from 427 comparisons
Number of subjects: 427
Study: 12854745

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (N2O)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sevoflurane anesthesia without N2O
Number of subjects: 40
Study: 9890317

Group type: EXPERIMENTAL
Intervention: Reused dialyzers with various germicides (Renalin, bleach, glutaraldehyde, heated citric acid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reused dialyzers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low‐flux and high‐flux dialyzers
Number of subjects: 0
Study: 8787366

Group type: EXPERIMENTAL
Intervention: Artemether (intramuscular, given for 5 days)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Mefloquine (single oral dose, 25 mg/kg/body-weight)
Number of subjects: 84
Study: 2005167

Group type: COMPARATOR
Intervention: Dynamic Hip Screw (DHS)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Gamma nail
Number of subjects: 100
Study: 6391154

Group type: EXPERIMENTAL
Intervention: 80-g vegetable-protein-supplemented diet (30 g animal and 50 g vegetable, diet B)
Number of subjects: 6

Group type: COMPARATOR
Intervention: 40-g protein diet (30 g animal and 10 g vegetable, diet A)
Number of subjects: 6
Study: 30583813

Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block (CFNB) with bupivacaine
Number of subjects: 65

Group type: COMPARATOR
Intervention: PAI with bupivacaine:liposomal bupivacaine mixture (LB group)
Number of subjects: 65
Study: 30318624

Group type: EXPERIMENTAL
Intervention: TAC-QD (once-daily tacrolimus)
Number of subjects: 125

Group type: COMPARATOR
Intervention: TAC-BID (twice-daily tacrolimus)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: TAC-QD
Number of subjects: 125
Study: 26459175

Group type: EXPERIMENTAL
Intervention: Metformin (2 g oral daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard systemic therapy (PEXG) without metformin
Number of subjects: 60
Study: 24176529

Group type: EXPERIMENTAL
Intervention: Dietary counseling with probiotics
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Dietary counseling with placebo
Number of subjects: 256

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 256
Study: 21876066

Group type: EXPERIMENTAL
Intervention: Adjunctive levetiracetam (20-100 mg/kg/d, mean 50.2 mg/kg/d)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Adjunctive levetiracetam
Number of subjects: 103
Study: 18314112

Group type: EXPERIMENTAL
Intervention: Early CC group (100 mg of clomiphene citrate daily starting after medroxyprogesterone acetate for 5 days)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Late CC group (100 mg of clomiphene citrate daily starting on day 3 of menses for 5 days)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Early CC group
Number of subjects: 212

Group type: COMPARATOR
Intervention: Late CC group
Number of subjects: 212
Study: 17259062

Group type: EXPERIMENTAL
Intervention: Perceived early pubertal maturation
Number of subjects: 1366

Group type: EXPERIMENTAL
Intervention: Associating with delinquent peers in 6th grade
Number of subjects: 1366

Group type: EXPERIMENTAL
Intervention: Early maturation
Number of subjects: 1366
Study: 15036178

Group type: EXPERIMENTAL
Intervention: Craniofacial growth in CLP group
Number of subjects: 218

Group type: COMPARATOR
Intervention: Craniofacial growth in normal group
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Growth timing and peak velocity
Number of subjects: 218
Study: 11583389

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract EGb 761
Number of subjects: 72

Group type: COMPARATOR
Intervention: Pentoxifylline
Number of subjects: 72
Study: 9840608

Group type: EXPERIMENTAL
Intervention: PRP-T vaccine administered at six, 10, and 14 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PRP-T vaccine administered at 10 and 14 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (meningococcal A/C polysaccharide vaccine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PRP-T vaccine (group 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PRP-T vaccine (group 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PRP-T vaccine (both groups)
Number of subjects: 0
Study: 7863249

Group type: EXPERIMENTAL
Intervention: Nizatidine 20 mg/h
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Nizatidine 10 mg/h
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Nizatidine (both doses)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 126
Study: 2510259

Group type: EXPERIMENTAL
Intervention: Rioprostil, 300 micrograms at bedtime for 6 months
Number of subjects: 190

Group type: COMPARATOR
Intervention: Ranitidine, 150 mg at bedtime for 6 months
Number of subjects: 190
Study: 811925

Group type: EXPERIMENTAL
Intervention: Tolbutamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arginine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arginine + Glibenclamide
Number of subjects: 0
Study: 31765956

Group type: EXPERIMENTAL
Intervention: Bacillus xiamenensis PM14 inoculation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Uninoculated plants under 200 mg kg-1 Cr stress
Number of subjects: 0
Study: 30426311

Group type: EXPERIMENTAL
Intervention: Leflunomide combined with prednisone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cyclophosphamide with concomitant prednisone
Number of subjects: 100
Study: 28318624

Group type: EXPERIMENTAL
Intervention: online hemodiafiltration
Number of subjects: 381

Group type: COMPARATOR
Intervention: high-flux hemodialysis
Number of subjects: 381
Study: 25487082

Group type: EXPERIMENTAL
Intervention: Elosulfase alfa 2.0 mg/kg administered weekly
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Elosulfase alfa 2.0 mg/kg administered every other week
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study: 23172889

Group type: EXPERIMENTAL
Intervention: MDMA-assisted psychotherapy
Number of subjects: 19
Study: 21492400

Group type: EXPERIMENTAL
Intervention: 1.62% testosterone gel (1.25 g, 2.5 g, 3.75 g, and 5.0 g)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 234
Study: 20307430

Group type: EXPERIMENTAL
Intervention: Plaster slipper (n=20)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Tubi-grip support (n=17)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 37
Study: 16513872

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 12809566

Group type: EXPERIMENTAL
Intervention: Treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 10827314

Group type: EXPERIMENTAL
Intervention: Modified technique (group M) with cephalad implantation of the graft in the ipsilateral iliac fossa and vascular anastomoses in the common iliac vessels
Number of subjects: 280

Group type: COMPARATOR
Intervention: Standard technique (group C) with implantation of the kidney in the contralateral iliac fossa and vascular anastomoses on the external iliac vessels
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Modified technique (group M)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Standard technique (group C)
Number of subjects: 280
Study: 8892364

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 93

Group type: COMPARATOR
Intervention: Nylidrin
Number of subjects: 93
Study: 1992928

Group type: EXPERIMENTAL
Intervention: m-xylene exposure (200 ppm for 4 hours)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control session (no m-xylene exposure)
Number of subjects: 9
Study: 6828617

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30691085

Group type: EXPERIMENTAL
Intervention: Cola (158 kcal)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Chocolate milk (224 kcal)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Fruit drink (154 kcal)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Water (0 kcal)
Number of subjects: 32
Study: 29447329

Group type: EXPERIMENTAL
Intervention: Vinflunine plus capecitabine (VC)
Number of subjects: 770

Group type: COMPARATOR
Intervention: Capecitabine alone
Number of subjects: 770
Study: 28515068

Group type: EXPERIMENTAL
Intervention: Low-fat dietary pattern intervention (target of 20% of energy from fat)
Number of subjects: 48835

Group type: EXPERIMENTAL
Intervention: Low-fat dietary pattern intervention
Number of subjects: 48835

Group type: COMPARATOR
Intervention: Usual diet comparison group
Number of subjects: 48835
Study: 25559914

Group type: EXPERIMENTAL
Intervention: Low dose exercise (150 min/week)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: High dose exercise (300 min/week)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 139
Study: 23432941

Group type: EXPERIMENTAL
Intervention: PTVE + EVL
Number of subjects: 88

Group type: COMPARATOR
Intervention: EVL
Number of subjects: 88
Study: 21619917

Group type: EXPERIMENTAL
Intervention: Ethanolic extract of Tulsi leaves (300 mg capsules)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 18288059

Group type: EXPERIMENTAL
Intervention: docetaxel cisplatin (4 cycles followed by 2 cycles of docetaxel alone if objective response or stabilisation)
Number of subjects: 300

Group type: COMPARATOR
Intervention: docetaxel alone (4 cycles followed by 2 cycles of docetaxel alone if objective response or stabilisation)
Number of subjects: 300
Study: 16894950

Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 0
Study: 14626181

Group type: EXPERIMENTAL
Intervention: Composite Salvia Injection (CSI) plus Western Medicine (WM)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Western Medicine (WM)
Number of subjects: 72
Study: 11099285

Group type: EXPERIMENTAL
Intervention: Non-directive counselling
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Cognitive-behaviour therapy
Number of subjects: 464

Group type: COMPARATOR
Intervention: Usual general practitioner care
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Non-directive counselling and Cognitive-behaviour therapy
Number of subjects: 464
Study: 9417975

Group type: EXPERIMENTAL
Intervention: Physostigmine (maximal tolerated dose individually determined)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 3
Study: 7801547

Group type: EXPERIMENTAL
Intervention: Combined method of x-ray and radiologic examinations of the lungs
Number of subjects: 0
Study: 3522371

Group type: EXPERIMENTAL
Intervention: Low sodium diet (21 mmol sodium per day)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Unrestricted sodium intake
Number of subjects: 140
Study: 29727013

Group type: EXPERIMENTAL
Intervention: Everolimus, target Cmin range of 5-7 ng/mL initially and 5-15 ng/mL for inadequate response.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Everolimus, TN-Cmin increases.
Number of subjects: 0
Study: 26227401

Group type: EXPERIMENTAL
Intervention: Music (M)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Video (V)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 98
Study: 24898154

Group type: EXPERIMENTAL
Intervention: Centrifugation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PureGraft
Number of subjects: 30

Group type: COMPARATOR
Intervention: Centrifugation and PureGraft
Number of subjects: 30
Study: 23931421

Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography (CCTA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Catheter coronary angiogram (CCA)
Number of subjects: 30
Study: 21920335

Group type: EXPERIMENTAL
Intervention: Atorvastatin monotherapy or atorvastatin-based combination therapies
Number of subjects: 33
Study: 18312050

Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system patch (10-30 mg, 9-hour wear time)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: OROS methylphenidate capsule (18-54 mg)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 282
Study: 16998403

Group type: EXPERIMENTAL
Intervention: Diet fortified with fish oil and arginine (FAD)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard diet (STD)
Number of subjects: 23
Study: 14550817

Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg/day) for 6 months
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg/day) and resistance exercises for 6 months
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 25